source
- Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapiesJazz Pharmaceuticals is adding to its orchestra of epilepsy treatments with the acquisition of Actio Biosciences for $820 million upfront.Fierce Biotech · 11h ago↗ source
- BioNTech appoints former Sobi chief Guido Oelkers as new CEOBioNTech has filled its long-vacant chief executive position after a six-month search. The board selected Guido Oelkers, Ph.D., who most recently led Swedish pharmaceutical company Sobi. At Sobi,…
- BioVie’s Parkinson drug data prompts 50% stock drop as company shifts to composite endpoint